Rhabdomyolysis caused by the moderate  CYP 3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review | Zendy

Hsiao S.H. | Zendy; Chang H.J. | Zendy; Hsieh T.H. | Zendy; Kao S.M. | Zendy; Yeh P.Y. | Zendy; Wu T.J. | Zendy

Premium

Rhabdomyolysis caused by the moderate CYP 3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review

Author(s) -

Hsiao S.H.,

Chang H.J.,

Hsieh T.H.,

Kao S.M.,

Yeh P.Y.,

Wu T.J.

Publication year - 2016

Publication title -

journal of clinical pharmacy and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 73

eISSN - 1365-2710

pISSN - 0269-4727

DOI - 10.1111/jcpt.12425

Subject(s) - rhabdomyolysis , atorvastatin , fluconazole , medicine , statin , drug , adverse effect , cyp3a4 , adverse drug reaction , pharmacology , antifungal , dermatology , cytochrome p450 , metabolism

Summary What is known and objective Rhabdomyolysis is a severe potential adverse drug reaction of statin therapy. We report a case of rhabdomyolysis due to drug–drug interaction ( DDI ) between atorvastatin and fluconazole and review the literature. Case summary A 70‐year‐old woman received atorvastatin for hyperlipidaemia without any problem for 4 years. When intravenous fluconazole was added for treating a fungal infection, rhabdomyolysis developed 2 weeks later. Removal of atorvastatin led to the resolution of her rhabdomyolysis. What is new and conclusion Our case demonstrates that in some subjects even a moderate CYP 3A4 inhibitor such as fluconazole may lead to rhabdomyolysis in subjects receiving a statin.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research